Eton Pharmaceuticals
Eton Pharmaceuticals

Eton Pharmaceuticals

Pharmaceuticals
WebsiteInvestor RelationsSEC
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

$1.9B

Market Cap • 11/10/2026

2017

(9 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

22,4

P/S

13,8

P/EBITDA

42,7

P/OCF

50,8

P/FCF

51

P/E

44,7

BVPS

3

EPS

1,5

Market Cap

Market Cap

1,9B

EV

1,9B

EV/Revenue

13,6

EV/EBITDA

42

EV/EBIT

47,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,3%

Total Yield

-0,3%

Payout

0%

Retained Earnings

-64,1M

Profitability

Gross Margin

69,2%

EBITDA Margin

32,4%

EBIT Margin

28,8%

Net Margin

35,3%

D&A/EBITDA

0%

R&D/Revenue

7%

Capex/Revenue

0,1%

Capex/D&A

2,7%

Capex/OCF

0,3%

SBC/OCF

19,3%

% PPE

0,9%

% Goodwill

0%

ROE

90,6%

ROIC

75,6%

Growth

CAGR Revenue 5Y

54,9%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

1,8

Quick Ratio

1,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium